Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Comment by Smokey1958on Aug 18, 2024 10:46am
121 Views
Post# 36184840

RE:Apparently the codes have been approved

RE:Apparently the codes have been approvedAbsolutely fantastic news, shediac! Not only that, the fee structure looks revenue generating. I like their accepted device price in establishing a starting point for determining coverage.

"To that end, we have identified and are using a commercial price of $1,19914 from an official distributor of Venowave in the United States.


As the price used in calculating the fee schedule amounts is greater than $150, payment would be made on a capped rental basis in accordance with our regulations at 42 CFR 414.229.


In accordance with regulations at 42 CFR 414.238(c), the 2024 price of $1,199 is deflated to the 1986 fee schedule base period using the percentage change in the consumer price index for all urban consumers (CPI-U) from the mid-point of the year the prices are in effect to the mid-point of the fee schedule base period. The price is then updated to the current year using the covered item update factors at section 1834(a)(14) of the Social Security Act.

Our preliminary determination is that the capped rental fee schedule amount would be approximately $78.05 on average for months 1 through 3, and approximately $78.05 on average for months 4 through 13, resulting in a total capped payment of $819.55 should there be 13 months of continuous use."





<< Previous
Bullboard Posts
Next >>